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Abstract 
Objective: We performed a randomized, double‑blind, cross‑over study to assess the neuroregenerative potential of 
intravenous granulocyte colony‑stimulating factor (G‑CSF) followed by infusion of mobilized peripheral blood mono‑
nuclear cells (mPBMCs) in children with cerebral palsy (CP).
Methods: Children with non‑severe CP were enrolled in this study. G‑CSF was administered for 5 days, then mPB‑
MCs were collected by apheresis and cryopreserved. One month later (M1), recipients were randomized to receive 
either mPBMCs or a placebo infusion, and these treatment groups were switched at 7 months (M7) and observed 
for another 6 months (M13). We assessed the efficacy of treatment by evaluating neurodevelopmental tests, as well 
as by brain magnetic resonance imaging‑diffusion tensor imaging (MRI‑DTI) and 18F‑fluorodeoxyglucose (FDG) brain 
positron emission tomography‑computed tomography (PET‑CT) scanning to evaluate the anatomical and functional 
changes in the brain.
Results: Fifty‑seven patients aged 4.3 ± 1.9 (range 2–10) years and weighing 16.6 ± 4.9 (range 11.6–56.0) kg were 
enrolled in this study. The administration of G‑CSF as well as the collection and reinfusion of mPBMCs were safe 
and tolerable. The yield of mPBMCs was comparable to that reported in studies of pediatric donors without CP and 
patients with nonhematologic diseases. 42.6% of the patients responded to the treatment with higher neurodevelop‑
mental scores than would normally be expected. In addition, larger changes in neurodevelopment test scores were 
observed in the 1 month after G‑CSF administration (M0–M1) than during the 6 months after reinfusion with mPBMCs 
or placebo (M1–M7 or M7–M13). Patients who received G‑CSF followed by mPBMC infusion at 7 months (T7 group) 
demonstrated significantly more neurodevelopmental improvement than patients who received G‑CSF followed by 
mPBMC infusion at 1 month (T1 group). In contrast to the results of neurodevelopment tests, the results of MRI‑DTI at 
the end of this study showed greater improvement in the T1 group. Although we observed metabolic changes to the 
cerebellum, thalamus and cerebral cortex in the 18F‑FDG brain PET‑CT scans, there were no significant differences in 
such changes between the mPBMC and placebo group or between the T1 and T7 group.
Conclusions: Neurodevelopmental improvement was seen in response to intravenous G‑CSF followed by mPBMC 
reinfusion, particularly to the G‑CSF alone even without mPBMC reinfusion. Further studies using a larger number 
of mPBMCs for the infusion which could be collected by repeated cycles of apheresis or using repeated cycles of 
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Background
Children with cerebral palsy (CP) have disabilities both 
from motor impairment and from related disorders in 
other functions, including sensation, cognition, commu-
nication, vision, and behavior. Although various strate-
gies have been used to improve neurologic impairment in 
patients with CP, most strategies used to date are com-
plementary therapies, and there is currently no medical 
treatment that can repair the damaged nervous tissues 
[1]. Recent studies revealed that persistent neuroinflam-
mation and associated apoptosis in brains affected by CP 
could be therapeutic targets [2]. Apoptosis is an attrac-
tive target because anti-apoptotic agents could be used to 
reverse apoptosis during a therapeutic time window after 
hypoxia-induced injury [3]. Other potential therapeutic 
targets include hematopoietic growth factors, such as 
erythropoietin (EPO) and granulocyte colony-stimulat-
ing factor (G-CSF), which influence the proliferation of 
neural stem and progenitor cells. EPO and G-CSF have 
specific receptors in the brain and both factors are pro-
duced in the brain [4, 5]. Therefore, EPO and G-CSF have 
been investigated for their ability to stop neurodegenera-
tive conditions [6, 7].
Recently, cell therapy has emerged as a potential treat-
ment for patients with CP. Bone marrow (BM)- or cord 
blood (CB)-derived mesenchymal stem cells (MSCs) have 
generally been used for cell therapy. In addition, intrave-
nous CB mononuclear cells (CB MNCs) or intrathecal 
BM MNCs have been also assessed for safety and efficacy 
in children with CP [8–12]. Studies show that in children 
with CP recovery from neurologic impairment is prom-
ising, but not complete, following stem cell therapy with 
CB MNCs. However, there are limitations to the use of 
CB MNCs and BM MNCs for repeated therapy, as there 
is only one opportunity to collect CB MNCs, and the 
procedure for extracting BM MNCs is very invasive in 
children with CP.
We hypothesized that mobilized peripheral blood 
mononuclear cells (mPBMCs) would be a better source 
of cell therapy for children with CP, if these cells had a 
similar neuroregenerative potential to BM/CB MNCs. 
Multipotent precursor cells exist in peripheral blood, and 
a fraction of elutriated blood cells from normal individu-
als contains MNCs that have the potential to be MSCs 
[13]. There are several advantages to using mPBMCs for 
cell therapy in children with CP: the G-CSF that is used 
to mobilize peripheral blood mononuclear cells (PBMCs) 
has neuroregenerative potential; the collection and frac-
tionation of stem cells can be repeated; and, the therapy is 
suitable for most children with CP. So far, there have been 
no clinical trials of cell therapy with autologous mPBMCs 
for children with CP. The current study describes a ran-
domized, double-blind, cross-over study of intravenous 
G-CSF followed by infusion with autologous mPBMCs 
in children with CP to determine the safety and feasibil-
ity of the procedure, as well as the potential efficacy for 
improving neurological impairment.
Methods
Study design
Patients were included in the study if they were between 
2 and 10  years of age and had a non-severe type of CP 
After baseline studies at enrollment (M0), intravenous 
G-CSF of 10  μg/kg was administered for 5  days. On 
the fifth day mPBMCs were collected with a single-day 
course of apheresis and then cryopreserved (Fig. 1). The 
detailed apheresis procedure is described in our previ-
ous study [14]. One month after cryopreservation of the 
mPBMCs (M1), patients were randomized to receive 
either mPBMCs or placebo. Six months after randomi-
zation (M7), cross-over infusion of mPBMCs or pla-
cebo was performed and the patients were observed for 
another 6  months. During the study, comprehensive 
physiotherapy and occupational therapy for individual 
patients were not modified. We assessed the neurode-
velopmental status of patients at M0, M1, M7, and M13 
after enrollment using various evaluation tools for neu-
rodevelopmental tests. Brain magnetic resonance imag-
ing-diffusion tensor image (MRI-DTI) and brain positron 
emission tomography-computed tomography (PET-CT) 
were used to evaluate the anatomical and functional 
changes in the brain at enrollment (M0), M7, and M13. 
This study was approved by the Institutional Review 
Board of Hanyang University Hospital (201103002).
Evaluation of neurodevelopment
We assessed the parents’ feeling for the changes of motor 
or cognitive functions during study periods of their chil-
dren, which even could not provide the clear and objec-
tive information on the neurodevelopmental evaluation. 
Comprehensive neurodevelopmental examinations were 
performed using the Denver development screening test 
G‑CSF alone, are needed to clarify the effect of mPBMC reinfusion or G‑CSF alone (Trial registration: ClinicalTrials.gov, 
NCT02983708. Registered 5 December, 2016, retrospectively registered).
Keywords: Cerebral palsy, Granulocyte colony‑stimulating factor, Mobilized peripheral blood mononuclear cells, 
Neuroregeneration
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II (DDST-II) to assess gross developmental screening, 
the pediatric evaluation of disability inventory (PEDI) 
to assess detailed developmental, the gross motor func-
tion classification system (GMFCS) to assess gross motor 
function staging, the gross motor function measure-88 
(GMFM) to assess detailed motor function, the manual 
ability classification system (MACS) to assess fine motor 
staging, and the quality of upper extremity skill test 
(QUEST) to assess fine motor function. The results for 
each examination tool were evaluated by well-trained 
physical and occupational therapists, and therapeutic 
responses were comprehensively assessed by rehabilita-
tion specialists.
Neuroimaging studies
Brain MRI
All patients underwent MRI examination using a 3.0T 
system (Achieva, Philips, Best, Netherlands). Conven-
tional images including axial T1-weighted, T2-weighted, 
and fluid-attenuated inversion recovery (FLAIR) were 
obtained for the anatomical evaluation. DTI data were 
obtained for the functional evaluation using a single shot 
echo planar sequence with the following parameters; 15 
diffusion gradient directions, maximum b value = 800 s/
mm2, TR/TE = 9000/55 ms, slice thickness = 2 mm. The 
DTI datasets were transferred to a workstation for pro-
cessing. Fractional anisotropy (FA) and apparent diffu-
sion coefficient (ADC) values for 18 regions of interest 
(ROIs) were obtained from the DTI data. All ROIs were 
set and analyzed by a pediatric neurologist.
Brain PET‑CT scanning
Brain PET images were acquired using a dedicated PET-
CT system (Biograph 6, Siemens Medical System, Knox-
ville, TN) at M0, M7, and M13 to monitor metabolic 
improvements of the brain. The patients fasted at least 6 h 
prior to PET-CT scanning. After intravenous injection of 
18F-FDG (3.7 MBq/kg, 33–207 MBq), patients waited for 
60 min in a dark room with a dim light before imaging, 
while 18F-FDG was distributed in brain. PET scans were 
obtained for 10 min, and images were reconstructed with 
a 168 × 168 matrix (pixel size = 1.95 × 1.95 mm with a 
slice thickness of 3.0 mm), and the ordered subset expec-
tation maximum iterative reconstruction algorithm, 
Fig. 1 Design of the clinical study. MRI-DTI magnetic resonance imaging‑diffusion tensor imaging; PET positron emission tomography; G-CSF 
granulocyte colony‑stimulating factor; mPBMC mobilized peripheral blood mononuclear cell. M0, M1, M7 and M13 refer to months after enrollment. 
T1 and T7 refer to a group who received mPBMC at 1 and 7 months of study, respectively
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an 5 mm Gaussian filter, and a 30 cm field of view. Two 
board-certified nuclear medicine physicians reviewed 
all three set of individual subject by visual assessment 
in consensus to check for the differences between the 
mPBMC group and placebo group, as well as T1 group 
and T7 group.
Data analyses
We analyzed the following: safety and yield of G-CSF-
mobilized PBMC collection; outcomes at M13; the 
booster effect of mPBMC infusion (by comparing the 
mPBMC group and the placebo group); and, outcomes 
according to mPBMC infusion time (T1 group: mPBMC 
infusion at 1  month after G-CSF infusion; T7 group: 
mPBMC infusion at 7 months after G-CSF infusion). The 
statistical software SAS for Windows (version 9.4, Cary, 
NC, USA) was used for data analysis. Logistic regres-
sion was used to analyze parental assessments, and the 
Mann–Whitney U test was used to analyze the neurode-
velopment tests. The Wilcoxon rank sum test was used 
to analyze data from the brain MRI-DTI and PET-CT 
scans. P values ≤0.05 were considered to be statistically 
significant.
Results
Demographic data
Fifty-seven patients were enrolled in the current study 
and their mean age and body weight were 4.3 ± 1.9 years 
(range 2–10  years) and 16.6  ±  4.9  kg (range 11.6–
56.0  kg), respectively. Types of CP were as follows: 31 
diplegia, 15 hemiplegia, 11 others (triplegia, ataxic, athet-
oid). Possible causes of CP were periventricular leukoma-
lacia (n = 37), hypoxic ischemic encephalopathy (n = 2), 
intracranial hemorrhage (n = 2), and unknown (n = 16). 
Forty-seven patients for whom complete study data were 
available were included in this analysis.
Safety of G‑CSF administration and yield of PBMCs
G-CSF-mobilized PBMC collection was safe in children 
with CP. We observed only two cases of fever and one epi-
sode of irritability during the G-CSF infusion. Transient 
hemoglobinuria (n = 3) and abdominal pain (n = 1) were 
reported during the mPBMC infusion, and these were 
resolved with supportive treatments. The total nucleated 
cell (TNC) count of mPBMCs was 5.97 ± 1.99 × 108/kg, 
and the TNC count of CD34+ cells was 3.07 ± 2.1 × 106/
kg. Pre-freezing and post-thawing cell data were not sig-
nificantly different between the two groups (T1 and T7), 
except for the post-thawing TNC counts, where the TNC 
count was significantly higher in the T7 group (Table 1).
Parental assessments
Even before randomization for mPBMC infusion at M1 
(i.e. during the one month after G-CSF administration), 
functional changes were noted by parents of 27 patients 
from the total group of 47 patients. After randomiza-
tion, at M13, functional changes were noted by parents 
of 41 patients in the mPBMC group and by parents of 45 
patients in the placebo group, although this difference 
was not statistically significant. There were also no sig-
nificant differences in the functional changes recorded by 
parents at M13 between the T1 and T7 groups (Table 2).
Neurodevelopmental tests
Although we observed no significant changes in the 
GMFCS and MACS domains, 20 of 47 patients (42.6%) 
showed overall improvement at M13 in the domains of 
GMFM, PEDI and QUEST. We defined overall improve-
ment as a score change in GMFM >4 points and/or score 
changes in PEDI >7 points in at least three items. The 
clinical characteristics of patients according to their over-
all therapeutic response are shown in Table 3. There were 
no risk factors associated with therapeutic responses; 
however, the number of responders was significantly 
higher in the T7 group than in the T1 group (p = 0.028). 
When comparing T1 and T7 groups (Table  4), the 
only significant score improvements were in the over-
all GMFM and GMFM-crawling domains, and these 
improvements were observed between enrollment and 
completion of study (M0–M13). Furthermore, when we 
compared the change in score after randomization (M1–
M13), the GMFM, GMFM-crawling and GMFM-sitting 
domains showed significant improvement in the T7 
group compared to the T1 group. Although there were 
no significant differences in neurodevelopment score 
improvement between mPBMC and placebo groups 
after randomization, more significant score changes in 
the GMFM, PEDI, and QUEST domains were observed 
before randomization (Table 5).
Table 1 Cell counts of cryopreserved and infused mPBMCs
mPBMC mobilized peripheral blood mononuclear cell; TNC total nucleated cell; 
T1 and T7 refer to a group who received mPBMC at 1 and 7 months of study, 
respectively
T1 (N = 28) T7 (N = 29) p
Pre‑freezing TNC (×108/kg) 5.84 ± 2.18 6.09 ± 1.89 0.574
CD34 (×106/kg) 3.16 ± 2.72 2.99 ± 1.40 0.678
Post‑thawing TNC (×108/kg) 4.63 ± 2.88 6.20 ± 1.94 0.018
CD34 (×106/kg) 1.92 ± 1.99 1.75 ± 1.07 0.837
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Brain MRI‑DTI scanning
In the MRI-DTI scans, there was a trend of increasing FA 
values and decreasing ADC values over time (M0–M13). 
However, these trends were not statistically significant, 
and there were also no significant differences between 
mPBMC and placebo groups (M1–M7 and M7–M13) in 
FA or ADC values in any ROIs. To evaluate the effect of 
mPBMC infusion on the changes in MRI-DTI scans, we 
analyzed the data according to the time of mPBMC infu-
sion. The FA and ADC values were significantly greater 
in the T1 group than in the T7 group for the left corona 
radiata (CRL), left posterior limb of internal capsule 
(PLL), and the ADC values were significantly decreased 
in genu ROIs between M0 and M13 (Table 6), and in PLL 
ROI between M0 and M7 (Table 6). However, there were 
no significant differences in any ROI between M7 and 
M13.
Brain PET‑CT scanning
Although we observed metabolic changes to the cerebel-
lum, thalamus and cerebral cortex in the brain PET-CT, 
there were no significant differences in the incidence of 
metabolic changes between the mPBMC and placebo 
groups, or between the T1 and T7 groups.
Discussion
We have performed a clinical trial using G-CSF and 
mobilized PBMCs in patients with CP, based upon the 
following backgrounds. The use of G-CSF in children 
with CP is ethical and beneficial because it is already 
proven to be safe in normal volunteer donors [15, 16], 
and G-CSF has the potential to induce neuroregenera-
tion in patients with neurodegenerative diseases [5, 7]. 
Also, the mobilization and apheresis of mPBMCs in chil-
dren are safe and effective [15], and mPBMCs contain 
MSCs which can be isolated and then secrete various 
cytokines potentially able to repair the damaged tis-
sues [13, 17]. Additionally, we have previously reported 
upon the safety of administering G-CSF and collect-
ing mPBMCs in children with CP [14], and we have also 
reported on the intracellular expression of neurotrophic 
factors and inflammatory cytokines, which could exert a 
Table 2 Number of patients for functional improvement by parental assessment according to randomization (before vs 
after) and time of mPBMC infusion (T1 vs T7)
mPBMC mobilized peripheral blood mononuclear cell; T1 and T7 refer to a group who received mPBMC at 1 and 7 months of study, respectively
+ p indicates statistical significances of items between placebo and mPBMC groups
*p indicates statistical significances of items between before T1 and T7 groups
Before randomization After randomization T1 T7 p*
Placebo mPBMC p+
Cognitive function 19 31 23 0.09 8 11 0.59
Motor function 3 0 2 0.15 0 0 –
Cognitive + motor function 5 14 16 0.65 13 14 0.83
No interval change 20 2 6 0.13 1 0 0.28
Table 3 Clinical characteristics according to overall therapeutic response, as measured by neurodevelopment tests
CP cerebral palsy; T1 and T7 refer to a group who received mobilized peripheral blood mononuclear cell at 1 and 7 months of study, respectively
a Responder refers to a patient showing overall improvement at M13 as measured by neurodevelopment tests
Total (number or mean ± SD) Responder (N = 20)a Non‑responder (N = 27) p
Sex 0.915
 Male 25 11 14
 Female 22 9 13
Age (years) 4.1 ± 1.9 3.2 ± 1.5 4.7 ± 1.9 0.968
Body weight (kg) 16.6 ± 7.70 13. 8 ± 2.57 18.5 ± 9.35 0.142
Infused TNC (×108/kg) 5.2 ± 2.54 5.7 ± 1.52 4.8 ± 3.04 0.847
CP type 0.215
 Diplegia 25 10 15
 Non‑diplegia 22 10 12
Infusion time 0.028
 T1 22 5 17
 T7 25 15 10
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neuroregenerative effect, in mPBMCs from children with 
CP [17].
In the current study, we demonstrated that G-CSF 
administration and collection/reinfusion of mPBMCs 
were safe and tolerable in children with CP. A single-
day apheresis in children with CP yielded TNC counts 
of 5.97  ±  1.99  ×  108/kg, and CD34+ cell counts of 
3.07  ±  2.1  ×  106/kg. These numbers are sufficient for 
hematopoietic reconstitution, although the target dose of 
MNCs or MSCs for cell therapy is yet to be determined. 
The yield of mPBMCs from children with CP was com-
parable to the yield from normal pediatric donors and 
patients with nonhematologic disease, reported in other 
studies [18, 19]. We cryopreserved all collected mPBMCs 
for at least 1 month and then reinfused them (after rand-
omization) at 1  month or 7  months. With this protocol, 
we tried to reveal the neuroregenerative effect of G-CSF 
alone, without circulating mPBMCs, as well as any possi-
ble augmented effect following reinfusion with mPBMCs.
We observed that 42.6% of patients showed overall 
responses in the neurodevelopment tests than would nor-
mally be expected. In addition, the largest neurodevelop-
ment score improvements were obtained during 1 month 
after G-CSF administration followed by mPBMC collec-
tion (M0–M1), suggesting that G-CSF alone, irrespec-
tive of circulating mPBMCs, can counter neurological 
impairment in children with CP. We also tried to assess 
the booster effects of mPBMCs on neurodevelopmental 
functions. Compared to the placebo group, the group that 
had a mPBMC infusion at 7 months experienced a greater 
improvement in neurodevelopmental functions than the 
group receiving a mPBMC infusion at 1 month. However, 
it should be pointed out that the higher infused cell doses 
in the T7 group were associated with neurodevelopmen-
tal improvement, because there is, as yet, no evidence 
that cell dose has an effect on neurologic improvements. 
In addition, Hara [20] and Hayashiji [21] reported that 
G-CSF positively affects the recovery of muscle mass, 
Table 4 Change in neurodevelopment test score according to time of mPBMC infusion
mPBMC mobilized peripheral blood mononuclear cell; GMFM gross motor function measure; PEDI pediatric evaluation of disability inventory; QUEST quality of upper 
extremity skills test. M0, M1, and M13 refer to months after enrollment. T1 and T7 refer to a group who received mPBMC at 1 and 7 months of study, respectively
M0–M13 M1–M13
T1 T7 p T1 T7 p
GMFM 4.28 8.30 0.002 2.90 6.37 0.001
 Lying 1.34 1.33 0.398 0.89 0.71 0.780
 Sitting 2.65 9.08 0.103 1.74 7.35 0.044
 Crawling 5.19 12.86 0.010 2.92 10.41 0.002
 Standing 4.78 7.18 0.093 3.50 5.13 0.079
 Walking 7.45 10.02 0.391 5.43 8.45 0.198
PEDI_selfcare 8.64 8.13 0.370 5.58 6.54 0.204
 Mobility 8.86 10.00 0.856 6.35 6.53 0.621
 Social function 13.78 9.33 0.327 9.54 6.28 0.296
 Selfcare (caregiver) 7.88 10.92 0.228 5.54 8.44 0.455
 Mobility (caregiver) 4.90 7.28 0.221 3.29 6.22 0.052
 Social function (caregiver) 11.45 14.65 0.236 8.87 12.13 0.208
QUEST 21.28 25.66 0.394 13.79 18.44 0.183
Table 5 Changes in neurodevelopment test scores accord-
ing to randomization
mPBMC mobilized peripheral blood marrow cell; GMFM gross motor function 
measure; PEDI_C pediatric evaluation of disability inventory self-care; PEDI_M 
pediatric evaluation of disability inventory mobility; PEDI_F pediatric evaluation 
of disability inventory social function; PEDI_CC pediatric evaluation of disability 
inventory mobility self-care with caregiver assistance; PEDI_MC pediatric 
evaluation of disability inventory mobility with caregiver assistance; PEDI_FC 
pediatric evaluation of disability inventory mobility social function with 
caregiver assistance; QUEST quality of upper extremity skills test
M0, M1, M7 and M13 refer to months after enrollment
+ p indicates statistical significances of items between placebo and mPBMC 
groups
* p indicates statistical significances of items between before randomization and 
after randomization
Before randomization 
(M0–M1)
After randomization 
(M1–M7 or M7–M13)
p*
Placebo mPBMC p+
GMFM 1.6738 0.4000 0.3725 0.479 0.001
PEDI_C 2.2787 0.5180 0.4928 0.764 0.006
PEDI_M 3.0212 0.6187 0.5419 0.998 0.005
PEDI_F 3.6106 0.6665 0.6536 0.930 0.042
PEDI_CC 2.4127 0.6115 0.5549 0.736 0.057
PEDI_MC 1.3191 0.5366 0.2558 0.092 0.030
PEDI_FC 2.5148 1.1481 0.6079 0.040 0.022
QUEST 9.0497 1.0815 1.3392 0.949 0.047
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therefore delayed effect of G-CSF on muscle regeneration 
may be contributed to synergistic improvement of neu-
rodevelopmental functions in T7 group. Contrary to the 
results from neurodevelopment tests, MRI-DTI showed 
greater increase of FA values in the CRL, PLL, and Genu 
ROIs in the T1 group than in the T7 group, indicating 
that the neuroregenerative effect of G-CSF coupled with 
mPBMC infusion is higher at 1 month than at 7 months.
Table 6 Changes in FA and ADC values
M0, M7, and M13 refer to months after enrollment
FA fractional anisotropy; ADC apparent diffusion coefficient; ROI region of interest; CRR corona radiata, right; CRL corona radiata, left; PLR internal capsule, posterior 
limb, right; PLL internal capsule, posterior limb, left; MBR midbrain, right; MBL midbrain, left; PonsR pons, right; PonsL pons, left; PTRR posterior thalamic radiation, right; 
PTRL posterior thalamic radiation, left; FR frontal, right; FL frontal, left; TR temporal right; TL temporal left; OR occipital right; OL occipital left; Spl splenium
ROI FA ADC
T1 T7 p T1 T7 p
a Changes in FA and ADC values between M0 and M13
CRR 0.028 0.035 0.849 0.017 −0.018 0.723
CRL 0.056 0.029 0.032 −0.016 −0.015 0.935
PLR 0.057 0.020 0.144 −0.023 −0.013 0.643
PLL 0.039 0.018 0.010 −0.057 0.039 0.010
MBR −0.010 0.028 0.397 0.001 0.121 0.723
MBL 0.024 0.001 0.349 −0.079 0.004 0.238
PonsR −0.010 0.011 0.071 −0.047 −0.051 0.849
PonsL 0.027 0.035 0.892 −0.049 0.016 0.041
PTRR 0.023 0.010 0.643 0.008 0.022 0.683
PTRL 0.016 −0.013 0.367 −0.003 −0.009 0.935
FR 0.023 0.006 0.807 −0.003 0.008 0.978
FL −0.003 0.000 0.605 −0.023 0.028 0.238
TR 0.046 0.004 0.367 −0.154 −0.045 0.683
TL 0.043 0.030 0.683 −0.002 0.003 0.849
OR 0.024 0.023 0.935 0.033 0.009 0.531
OL 0.023 0.039 0.461 0.025 −0.035 0.605
Genu 0.055 0.027 0.238 −0.35 −0.001 0.026
Spl 0.019 0.044 0.285 0.004 −0.112 0.091
b Changes in FA and ADC values between M0 and M7
CRR −0.011 0.041 0.070 −0.055 −0.034 0.845
CRL 0.017 0.009 0.499 −0.059 −0.033 1.000
PLR 0.003 −0.005 0.963 −0.058 −0.019 0.767
PLL 0.028 0.016 0.521 −0.084 0.009 0.020
MBR −0.008 −0.003 0.521 −0.023 0.180 0.181
MBL 0.017 −0.007 0.481 −0.028 −0.053 0.913
PonsR 0.006 −0.007 0.964 −0.074 −0.017 0.105
PonsL 0.028 0.011 0.775 −0.063 −0.003 0.284
PTRR −0.011 0.019 0.424 −0.033 0.019 0.839
PTRL −0.003 −0.011 0.696 −0.045 −0.071 0.462
FR 0.013 −0.015 0.189 −0.063 −0.002 0.313
FL −0.003 −0.035 0.298 −0.060 0.011 0.599
TR 0.006 0.007 0.845 −0.125 −0.031 0.940
TL 0.007 0.017 0.408 −0.047 −0.011 0.775
OR −0.010 0.002 0.397 −0.044 −0.012 0.415
OL −0.005 0.005 0.754 −0.095 −0.048 0.397
Genu 0.032 0.002 0.271 −0.107 0.025 0.070
Spl −0.026 0.001 0.093 0.033 −0.040 0.490
Page 8 of 9Rah et al. J Transl Med  (2017) 15:16 
Given these differences between the results of neurode-
velopment tests and the changes observed in MRI-DTI 
scans, the neuroregenerative effect of mPBMC reinfusion 
may be minimal and/or the additive effect of G-CSF on 
the central nervous system as well as muscles could be 
considered. Furthermore, the collection and reinfusion of 
mPBMCs after G-CSF administration may not be essen-
tial because G-CSF could synergize with endogenous cir-
culating mPBMCs. Although we could not demonstrate 
the effect of G-CSF on muscle and an additional effect of 
mPBMCs on the changes of FA/ADC values in the MRI-
DTI scans, several investigators have found a correlation 
between ROI-based FA and clinical motor outcome in 
children with CP [22–24]. Therefore, future studies using 
MRI-DTI would be needed to reveal the association of 
infusion timing or cell doses of mPBMCs and clinical 
outcomes in children with CP.
Conclusion
We observed a neuroregenerative potential of intrave-
nous G-CSF followed by mPBMC reinfusion. The neu-
rodevelopmental improvement observed may have been 
caused by G-CSF alone without a contribution from the 
reinfused mPBMCs. Further studies using higher con-
centrations of mPBMCs which could be collected by 
repeated cycles of apheresis or using repeated cycles 
of G-CSF  alone are needed to clarify any benefit of 
mPBMC reinfusion or G-CSF alone.
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